Benzinga
T2 Biosystems Q2 Sales Below Expectations, Sticks To Annual Guidance
T2 Biosystems Inc’s (NASDAQ: TTOO) Q2 revenue reached $5.9 million, including product revenue of $2.6 million, representing decreases of 12% Y/Y and 30%, respectively, driven by lower sales of T2SARS-CoV-2 tests. The sales came in at the lower end of the interim sales, missing the consensus of $6.13 million. In Q2, the company executed 12 T2Dx Instruments contracts, including 6 in the U.S. and six outside the U.S., +300% Y/Y. Generated core sepsis test revenue of $1.2 million, a Y/Y decrease of